STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive: Some of these inhibitors bind STAT5 proteins in a nanomolar range and inhibit the tyrosine phosphorylation of STAT5 and CML/AML cell growth in a micromolar range [15,16,17].